No Data
No Data
Are Investors Undervaluing Stride (LRN) Right Now?
SyntheticMR Receives Regulatory Approval for SyMRI 15 in Switzerland
How Vance and Walz Will Try to Win the Debate
Stride, Inc. Wins Tech & Learning 2024 Back to School Award for Excellence in Secondary Education
Those Who Invested in Stride (NYSE:LRN) Five Years Ago Are up 221%
Express News | Alumis Presents 28-Week Data From Open Label Extension Period Of Phase 2 STRIDE Trial Of ESK-001; Says '28-week Data Show ESK-001 Was Generally Well Tolerated and Most Patients Treated With the Top Dose of 40 Mg Twice Daily Achieved PASI 75'
No Data
No Data